Welcome to our dedicated page for Erasca news (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.
Erasca, Inc. (Nasdaq: ERAS) is a clinical-stage precision oncology company dedicated to discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Their mission, embodied in their name, is to 'erase cancer'. The company's innovative approach aims to not just treat but potentially cure cancer by targeting and shutting down the RAS/MAPK pathway, which plays a crucial role in many types of cancer.
Erasca’s robust clinical pipeline includes promising drug candidates such as Naporafenib, a pan-RAF inhibitor with first-in-class potential targeting NRASm melanoma and RAS Q61X tissue agnostic solid tumors. The company's other notable candidates include ERAS-007, a highly selective oral ERK1/2 inhibitor, and ERAS-601, an oral SHP2 inhibitor, which target different nodes of the RAS/MAPK pathway. These efforts are supported by recent collaborations with industry giants like Novartis, who are providing crucial compounds like trametinib (MEKINIST®) for combination trials.
On the financial front, Erasca is well-funded with significant investments from both new and existing investors, having recently raised approximately $45 million in a private placement expected to close in April 2024. As of December 2023, the company reported $322 million in cash, cash equivalents, and marketable securities, ensuring a solid runway into the second half of 2026.
Among their latest achievements, Erasca has received FDA Fast Track Designation (FTD) for Naporafenib in combination with trametinib for advanced NRASm melanoma. This designation facilitates accelerated development and review processes, reflecting the potential of their therapies to address unmet medical needs.
The company’s pivotal Phase 3 SEACRAFT-2 trial for Naporafenib in post-immunotherapy settings for NRASm melanoma is slated to begin in the first half of 2024. Additionally, Erasca has announced exciting new partnerships and pipeline enhancements, including in-licensing two preclinical RAS programs, ERAS-0015 and ERAS-4001, to further solidify their leadership in the precision oncology space.
For more up-to-date information on Erasca, Inc., including their latest financial results and key upcoming milestones, visit their official website or recent press releases.
Erasca, Inc. (Nasdaq: ERAS) announced six poster presentations at the AACR Annual Meeting, scheduled for April 8-13, 2022, in New Orleans. The presentations will focus on key product candidates, including ERAS-007, a selective ERK1/2 inhibitor, and ERAS-601, a potent SHP2 inhibitor. Notably, ERAS-601 exhibits strong anti-tumor activity in RAS/MAPK-driven models. Details of the presentations, including dates, times, and locations, are outlined in the announcement. Erasca aims to advance therapies targeting RAS/MAPK pathway-driven cancers.
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, announced its participation in the Guggenheim Healthcare Talks 2022 Oncology Day. The event, featuring CEO Jonathan E. Lim and CFO David M. Chacko, will take place in a virtual format on February 10, 2022, at 2:30 PM ET. The company will also engage in one-on-one investor meetings. A live webcast will be available at Erasca.com/events, with an archived replay for 30 days afterward. Erasca focuses on therapies for RAS/MAPK pathway-driven cancers.
Erasca, Inc. (Nasdaq: ERAS) announces key leadership changes with Lisa Tesvich-Bonora appointed as Chief People Officer and Robert Shoemaker promoted to Senior Vice President of Research. Tesvich-Bonora, with over 20 years of experience in organizational development, will lead initiatives in recruitment and professional development. Shoemaker, one of the company’s founding members, will integrate Discovery Research activities to enhance the development of Erasca’s oncology pipeline. These appointments aim to strengthen Erasca's culture and research capabilities.
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, will participate in the 40th annual J.P. Morgan Healthcare Conference on January 10, 2022, at 3:45 PM ET. During the event, CEO Jonathan E. Lim will present an overview of the company and its pipeline. Additionally, Dr. Lim and CFO David M. Chacko will engage in one-on-one investor meetings. A live audio webcast of the presentation will be accessible online, with an archived replay available for 30 days afterward.
Erasca has achieved FDA clearance for its investigational new drug (IND) application for ERAS-801, an EGFR inhibitor, ahead of schedule. This drug is designed for high CNS penetration to treat recurrent glioblastoma multiforme (rGBM) and will enter the THUNDERBBOLT-1 Phase 1 clinical trial in Q1 2022. The collaboration with the Global Coalition for Adaptive Research (GCAR) aims to explore a path for ERAS-801 within the GBM AGILE trial, enhancing the potential for expedited therapy development. With about 125,000 annual rGBM cases worldwide, this advancement addresses a significant unmet need.
Erasca, Inc. (Nasdaq: ERAS) has been added to the NASDAQ Biotech Index, effective December 20, 2021. This index tracks biotech and pharmaceutical companies listed on the Nasdaq, and membership requires meeting specific criteria, including market capitalization and trading volume. Erasca focuses on developing therapies for RAS/MAPK pathway-driven cancers and is backed by experts in precision oncology. This inclusion indicates recognition of the company's growth and stability in the biotechnology sector.
Erasca, Inc. (Nasdaq: ERAS), a precision oncology company focused on RAS/MAPK pathway-driven cancers, will participate in the Evercore ISI 4th Annual HealthCONx Conference on December 2, 2021. Jonathan E. Lim, M.D., CEO, and David M. Chacko, M.D., CFO, will engage in a "Fireside Chat" at 3:05 PM ET. Investors can register for the live webcast at Evercore.webcasts, with an archived replay available for 30 days on Erasca.com/events.
Erasca aims to develop innovative therapies targeting cancer pathways, leveraging expertise from top pioneers in the field.
Erasca, Inc. (Nasdaq: ERAS) reported strong execution in its recent financial results for Q3 2021, highlighting the initiation of two clinical trials for ERAS-007 in lung and gastrointestinal cancers. The company maintained a robust cash position of $487 million, bolstered by a $345 million IPO. Notably, it was named one of Fierce Biotech's "Fierce 15" innovative companies. However, the firm reported a net loss of $46.1 million for the quarter, influenced by significant R&D and G&A expenses, including a $17.5 million donation to the Erasca Foundation.
Erasca, Inc. (Nasdaq: ERAS) presented promising preclinical data for ERAS-801, a new EGFR inhibitor with significantly enhanced CNS penetration, at the AACR Conference. ERAS-801 shows a CNS penetration rate four times higher than existing EGFR inhibitors, demonstrating potent efficacy in over 90% of tested EGFR-mutant glioblastoma models. The company plans to submit an IND for refractory glioblastoma in Q1 2022. These advancements highlight ERAS-801's potential to improve outcomes for patients suffering from this aggressive cancer type.
FAQ
What is the current stock price of Erasca (ERAS)?
What is the market cap of Erasca (ERAS)?
What is Erasca, Inc.'s primary focus?
What are the key drugs in Erasca’s pipeline?
What recent achievements has Erasca reported?
How is Erasca funded?
What partnerships has Erasca entered into?
What is the SEACRAFT-2 trial?
What does FDA Fast Track Designation mean for Erasca?
What financial milestones has Erasca achieved recently?
What is the significance of Erasca's mission statement?